探索以中医瘀血阻络病机理论指导抗糖尿病中药筛选的研究
|
摘要
糖尿病(diabetes mellitus)是由于遗传和环境因素相互作用,导致胰岛素绝对或相对分泌不足以及靶组织细胞对胰岛素敏感性降低,引起蛋白质、脂肪、水和电解质等一系列代谢紊乱综合征。糖尿病患者长期血糖升高可致器官组织损害,引起脏器功能障碍以致功能衰竭。由于糖尿病的严重危害性及发病率的逐年增高,再加上治疗需要高额的费用,使得预治糖尿病已成为世界各国面临的严峻挑战;也使抗糖尿病药物具有巨大的市场前景,抗糖尿病新药的研发亦成为全球热点之一。
由于1型糖尿病发病率较低,不到5%,而且主要依赖胰岛素治疗,所以本研究主要针对2型糖尿病。
对2型糖尿病的认识半个多世纪以来一直局限在胰岛素分泌不足上,对其治疗自然也就主要集中在促进胰岛细胞对胰岛素的分泌上;药物的研发亦主要集中在胰岛素促泌剂上,导致治疗手段长期相对匮乏。
胰岛素抵抗(Insulin resistance,IR)是胰岛素的外周靶组织对胰岛素的敏感性与反应性降低,从而导致胰岛素难以产生正常的生理效应。研究表明,IR是2型糖尿病发病的关键驱动因素,也是一系列代谢异常,并导致心血管等并发症的核心,是产生糖尿病、冠心病、高血压等疾病的“共同土壤”。因此,针对IR的治疗是治疗2型糖尿病的关键。
由于对2型糖尿病发病机理的认识发生了根本性的转变,从对胰岛细胞本身的分泌功能的重视,转移到对胰岛素抵抗和胰外作用的重视上来,导致药物的研发速度不断加快,通过改善胰岛素抵抗来治疗2型糖尿病的新药便不断问世。
糖尿病属中医的“消渴病”。中医对消渴病的病机认识,自古迄今大都认为是阴津亏损,燥热内盛;医生按照肺、胃、肾三消论治。但自当代施今墨、祝谌予氏创立气阴两虚和瘀血阻络病机学说以来,已被大多数临床医生所接受,极大地推动了对消渴病病机的研究。随后痰、湿、毒致病等各种病机学说被不断地提出,极大地丰富了对消渴病发病机理的认识,使得临床疗效不断提高。由于对消渴病病因病机认识的不断深化,使得近十余年来抗糖尿病中药新药品种从无到有、增长迅猛。据季绍良报道,1985年～1992年未见有申报批准治疗糖尿病的中药新药;1992年～1999年4月,共批准14个;而1999年～2002年已批准临床研究的达到约30个。
但是,目前临床上抗糖尿病药物仍然是以西药为主,中药仍处于辅助地位。究其原因:一是中药新药研发依然沿袭西药新药研发的思路,主要精力都集中在有效成分提纯和药理作用研究上;二是新药处方设计缺乏中医病因病机理论和中药配伍理论的指导,药物筛选局限在古方、验方上;三是新药研发者与临床联系不紧密,研发思路落后于临床实践,对糖尿病的认识仍然局限在阴虚燥热、气阴两虚的病机上,一些病机新理论如:瘀血、痰湿、热毒等,则还没有进入抗糖尿病新药研发者的视野。因此,充分发挥中医药理论的指导作用,针对瘀血、痰湿和热毒等病机新理论,有目标地扩大药物筛选范围,研发疗效确切的抗糖尿病中药新药就是我们的当务之急。
现代中医病机理论认为,气阴两虚——阴虚燥热——阴阳两虚是2型糖尿病发生、发展的基本规律,而“瘀血阻络”则贯穿2型糖尿病的始终。气为血帅,气虚致血行无力;而“阴虚必血滞”,血流缓慢易凝滞血瘀。临床研究表明,2型糖尿病血瘀证与胰岛素抵抗密切相关。临床研究还表明,活血化瘀法对降低血糖和防治并发症均具有显著疗效。
本研究在胰岛素抵抗——“共同土壤说”和瘀血阻络——“共同病机说”的理论启发下,选择复方丹参片类制剂——即具有活血化瘀功效的、常用于治疗冠心病的小复方制剂——作为切入点,针对糖尿病胰岛素抵抗和瘀血阻络这个关键环节,首先对其进行抗糖尿病作用的临床和实验验证,探讨不同类的活血化瘀药物降血糖的可能性,以期能够有目标地拓展抗糖尿病有效部位的筛选范围;然后对其进行拆方研究,筛选有效部位,观察其降低血糖和防治糖尿病慢性并发症的效果,并探讨其作用机制,为下一步进行有效部位重新组方打下基础;并探索一条抗糖尿病中药新药筛选的新途径。
具体研究内容及结果如下:
西医学认为,胰岛素抵抗是2型糖尿病发生发展主要因素,2型糖尿病和冠心病有共同的发病土壤——胰岛素抵抗;中医学认为,瘀血既是糖尿病的病理产物,又是糖尿病发生发展的动因,2型糖尿病和冠心病都有共同的的发病机理——瘀血阻络。据此,我们推测凡是具有活血化淤作用的能够治疗冠心病的中药制剂都有可能用于治疗胰岛素抵抗的2型糖尿病。
首先,我们对活血化瘀法治疗冠心病的代表性中成药——复方丹参片和复方丹参注射液,进行2型糖尿病的临床疗效对照研究,结果表明:复方丹参片和复方丹参注射液均具有一定的降低血糖、增加胰岛素敏感性、改善临床症状的作用;与对照组比较,在消除临床症状、提高胰岛素敏感性方面更胜一筹。
其次,我们根据复方丹参片类制剂(即具有活血化瘀功效的、常用于治疗冠心病的小复方制剂)药味少、活性部位相对明确、研究较为简便的特点,选择了复方丹参滴丸、速效救心丸、地奥心血康胶囊以及复方丹参片与罗格列酮作比较,进行了降血糖的实验验证,发现它们都显示出一定的降血糖效果,同时,都能够提高胰岛素敏感指数;其中复方丹参片效果最好,这为我们下一步的筛选指明了方向。本实验结果充分证明,在中西医理论的指导下,我们可以缩小新药研发的筛选范围,使无目标的撒网式筛选变成有目标的猎取式筛选,取得事半功倍的效果。
第三,我们根据复方丹参片中主要成分性质不同,将其拆分成水溶性部位和脂溶性部位,并进行抗糖尿病的实验研究,发现复方丹参片水溶性部位、脂溶性部位均具有降低血糖、改善胰岛素抵抗的作用,但复方丹参片水溶性部位作用相对较强。
第四、我们将复方丹参片水溶性部位进行进一步拆分和重新组万,并进行抗糖尿病的实验研究,结果显示:除三七皂苷组之外,丹酚酸组、丹酚酸+三七皂苷组、丹酚酸+三七皂苷+冰片组血糖均显著下降。其中,丹酚酸+三七皂苷+冰片的血糖下降幅度最大。我们还发现了丹酚酸类这个具有显著降血糖作用的新部位。
第五、我们对复方丹参片有效部位拆方进行了抗糖尿病作用机理探讨,发现它们能够抑制超氧化物MDA,修复胰腺组织;降低血浆FFA、TNF—α,增强胰岛素受体的敏感性;提高ISR-1、IRS-2和PI3K的表达水平,减轻胰岛素受体后的抵抗;并且降低TG、改善脂肪肝,减少肝糖原的输出;通过以上多环节、多途径、多靶点的作用来达到控制血糖、治疗2型糖尿病的目的。还发现了丹酚酸+三七皂苷+冰片组这一新组方在改善胰岛素抵抗、减轻胰岛细胞损伤、改善脂代谢、抑制脂肪肝等多方面都有明显作用和独特优势,值得进一步的开发研究。
第六,我们的研究还发现,复方丹参片可能通过减少糖尿病大鼠糖基化产物、降低血脂、抑制组织过氧化产物的产生及组织增生来改善2型糖尿病大鼠慢性并发症。病理组织学检查显示,复方丹参片抑制模型大鼠眼球小血管血栓形成的作用极为显著,可改善眼球血液循环;能减轻模型大鼠动脉硬化或病变的程度;减轻模型动物坐骨神经损伤程度;能抑制模型动物肾脏系膜内浆液浸润、肾小管基膜增厚,减轻肾脏病变程度。
本研究的创新之处主要有三点:一是尝试运用中医瘀血阻络的糖尿病病机理论指导,并成功地将复方丹参片类制剂移植到2型糖尿病的治疗上,发现了复方丹参类制剂——复方丹参滴丸、速效救心丸、地奥心血康胶囊都有一定的降血糖作用,有效地缩小了抗糖尿病中药的筛选范围,初步验证了中医瘀血阻络病机理论对抗糖尿病中药筛选的指导意义。二是发现了丹参中的丹酚酸类部位具有明显的降低2型糖尿病模型大鼠血糖的作用。丹酚酸类的降血糖功效在以往的文献中尚未见报道,这是一个令人鼓舞的新发现,说明如果有理论的指导,筛选将更有针对性,筛选的效率会更高。三是我们还发现丹酚酸+三七皂苷+冰片组这一新组方通过改善胰岛素抵抗、减轻胰岛细胞损伤、改善脂代谢、抑制脂肪肝等多个方面作用,达到抗糖尿病的目的,值得进一步的开发研究。
总之,本实验研究对运用中医病机理论指导抗糖尿病药物筛选进行了有益尝试,发现了一些好的苗头,值得我们进行深入探讨,不断总结经验,以期建立一种新的中药新药筛选与研发模式。
Diabetes is a series of metabolic disorder syndrome in protein, fat, water and electrolytes, which due to the interaction of genetic and environmental factors, and causes absolutely or relatively to shortage of insulin secretion and sensitivity decrease of target cells to insulin. Diabetic patients with long-term elevated blood sugar can cause organ damage, which leads to function failure due to the viscera dysfunction. Because of the serious harmfulness of diabetes and the incidence rate increases year by year, coupling with the need for the high cost, which has become the world to face a serious challenge to prevent and therapy diabetes. Likewise, anti-diabetes drugs also have great market prospects, which makes anti-diabetes drugs researched and developed to become one of the focus in the world.
As the incidence of type 1 diabetes is low, less than 5 percent, and mainly relies on insulin therapy, this study is for type 2 diabetes primarily. The knowledge about type 2 diabetes has been confined to the lack of insulin secretion more than half a century, which causes the treatment for it has been focused on promoting insulin secretion agent naturally. Drugs research and development has been focused on promoting insulin secretion agent, leading to the relative lack of long-term treatment.
Insulin resistance (Insulin resistance, IR) is the peripheral insulin target tissues to insulin sensitivity and responsiveness decreases, leading to it is difficult for insulin to produce the normal physiological effects. Research shows that IR is the key driving factor leading to the incidence of type 2 diabetes. It is also a range of metabolic disorders, leading to cardiovascular complications such as the core. It is the "common soil" where diabetes, coronary heart disease and hypertension happen. Therefore, the treatment for IR is the key of treating type 2 diabetes.
Since the awareness about the pathogenesis of type 2 diabetes have changed fundamentally, the attention of which transits from the islet cells their own secretion to the action of IR and outside the pancreas. It leads to drug research and development continuing to accelerate, which causes that it is constantly available to improve insulin resistance to the treatment of type 2 diabetes drugs.
Diabetes belongs to Chinese medicine "wasting-thirst". The awareness about the pathogenesis of "wasting-thirst" has been considered to be the deficiency of body fluid that causes dryness-heat being excessive in the interior. Doctors take the way of treatment for diabetes in accordance with the lung, stomach and kidney. However, since the deficiency of both vital energy and yin and stagnation of blood theory has been founded by Shi jinmo and zhu chenyu this contemporary, which has been accepted by the majority of clinicians. It drives enormously to have research on the pathogenesis of diabetes. Subsequently, sputum, humid, and harm as such pathogenesis theories were constantly raised, greatly enriching the awareness on the pathogenesis of diabetes, which makes therapeutic effect continue to increase. The awareness for pathogeny and pathogenesis of "wasting-thirst" has deepened constantly, which makes anti-diabetes drugs varieties of Chinese medicine from scratch to rapid growth in nearly past 10 years. According to the report by Ji shoaling, the approval of new Chinese medicine treatment of diabetes drug have not been declared from 1985 to 1992; 14 had been approved from 1992 to April 1999; while about 30 had been approved to have clinical research from 1999 to 2002. However, the current clinical anti-diabetes drug is still mainly western medicine, Chinese medicine is still in secondary status. The reasons: First, traditional Chinese medicine research and development of new drugs continues to follow the thinking of western medicine research, the main efforts are concentrated on active ingredients purification and research on the pharmacological effects; Second, the design of new Chinese medicine prescription lacks guiding of pathogeny and pathogenesis theory of Chinese medicine and Chinese medicine compatibility theories, drugs selecting confined to the ancient prescription and experimental prescription. Third, the researchers of new drugs are not closely associated with the clinic, the ideas of research and development drop behind the clinical practice. The awareness of diabetes is still confined to the pathogenesis of deficiency of yin feverish sensation and deficiency of both vital energy and yin. Some new theories of pathogenesis such as blood stasis, phlegmatic hygrosis, pyretic toxicity have not enter into the the vision of the anti-diabetes drug researchers. Therefore, it is urgent to take full advantage of the guiding of Chinese medicine theory, for the new pathogenesis theory of blood stasis, phlegmatic hygrosis, pyretic toxicity, expanding the scope of drugs selected with aim, researching and developmenting certain effect of the anti-diabetes drug Chinese medicine.
The pathogenesis of modern traditional Chinese medicine theory considers that deficiency of both vital energy yin-deficiency of yin feverish sensation-simultaneous asthenia of yin and yang is the basic rule for the occurrence and development of the type 2 diabetes, while the blocking collaterals of blood stasis traverses from the beginning and the end of type 2 diabetes. Qi is the commander of blood, the deficiency of qi causing it incapable to circulate, while deficiency of yin must cause blood stasis, slow flow blood easily leads to blood stagnation. Clinical studies show that blood stasis of type 2 diabetes is closely related to insulin resistance. They also show that it is significantly effective to lower blood sugar and prevent complications for activating blood to resolve stasis treatment.
This study is inspired by the theory of insulin resistance- the "common soil" and blood stasis blocks collaterals-"common pathogenesis theory", selecting compound Danshen tablet generic medicine, that is, it has the effect of activating blood to resolve stasis and the small compound preparation which is often used to therapy coronary heart disease - as a point of penetration. Facing the key link of insulin resistance and blood stasis blocks collaterals, first of all its anti-diabetic role of the clinical and experimental verification, discussing the possibility of lowering blood sugar about different types of activating blood to resolve stasis drugs, expecting to develop the selected scope of anti-diabetic effective parts with aim. Then demolition research has been done and the effective parts are selected. Observing the effect of its lowering blood sugar and prevent chronic complications of diabetes, discussing its mechanism, which lays the foundation to form medicine over again about effective parts for the next step. To explore a new way of selecting anti-diabetes Chinese medicine.
Modern medicine considers that insulin resistance is the major factor which causes type 2 diabetes to start and develop. Type 2 diabetes and coronary heart disease have a common soil - insulin resistance. Traditional Chinese Medicine considers that blood stasis is not only the pathology production of diabetes, but also is the agent of the occurrence and development of diabetes. Type 2 diabetes and coronary heart disease have a common pathogenesis- blood stasis blocks collaterals. Accordingly, we speculate that any Chinese medicine formulations relieving blood stasis role can therapy coronary heart disease, which may also be used for the treatment of type 2 diabetes caused by insulin resistance.
First of all, we have a control research on the clinical efficacy of type 2 diabetes about the representative Chinese medicines to therapy coronary heart disease which can relieve blood stasis-compound Danshen tablet and compound Danshen injection. The results indicate that compound Danshen tablet and compound Danshen injection can lower blood sugar, increase insulin sensitivity and improve the clinical symptoms in a way. They are superior to the control group in the elimination of clinical symptoms and improvement of insulin sensitivity.
Secondly, due to these Chinese medicine are made up of a few ingredients, relatively clear active parts, so we choose Fufang danshen diwan, Suxiao jiuxin wan, Diao xinxuekang capsule and Fufang danshen tablet to compare with Rosiglitazone, and have experimental verification of lowering blood sugar, which showed that they all show some certain effect of lowering blood sugar. At the same time, they all can improve insulin sensitivity index. Among them, Fufangdanshen tablet is the best, which points out the direction t for our selecting of the next step. The results of this study fully demonstrate that under the guidance of traditional Chinese medicine, we can take the effect of getting twice the result with half the effort, by narrowing the selection scope of new drug research and development, which makes no goal-selecting of the nets become the hunt for selecting with aim.
Third, due to the major components of a different nature in Fufang danshen tablet, it is split into water-soluble part and fat-soluble part, the experimental anti-diabetes research is done. It is found that both water-soluble part and fat-soluble part of Fufang danshen tablet can lower blood sugar and improve insulin resistance, but the action of water-soluble part is relatively stronger than that fat-soluble part.
Fourth, water-soluble part of Fufang danshen tablet is further split into and re-group and the experimental research is conducted on the anti-diabetes. The results show that blood sugar decreases significantly in the salvianolic acid group, the salvianolic acid+ notoginsenoside group and the salvianolic acid+ notoginsenoside+ borneol group in addition to notoginsenoside group. Among them, blood sugar of the salvianolic acid+ notoginsenoside+ borneol group decreases most severely. We also find that the new section of the salvianolic acid which can lower blood sugar significantly.
Fifth, the mechanism of anti-diabetes is discussed by splitting the effective parts of Fufang danshen tablet. It is found that they can depress superoxide dismutase MDA and repair pancreatic tissue. They can reduce plasma FFA, TNF-α, enhance the sensitivity of insulin receptors. They can improve the expression of ISR-1, IRS-2 and PI3K and reduce the insulin resistance. They also lower TG, improve fatty liver and reduce the output of liver glycogen. It is the aim to control blood sugar and therapy type 2 diabetes by much more links, multi-channel and multi-role target. It is also found that the new group medicine of the salvianolic acid+ notoginsenoside+ borneol group has obvious role and unique advantages in improving insulin resistance, reducing the islet cell damage and improving fat metabolism and depressing fatty liver, which is worth the further development of research.
Sixth, the study also found that maybe Fufang danshen tablet improves the proliferation of type 2 diabetic rats' chronic complications by reducing the glycosylation product, lowering blood fat and depressing organized suppression of the product produced. Pathological examination reveals that the action of depressing the model rats' small vascular thrombosis in the eyeball is extremely significant for Fufang danshen tablet, which can improve blood circulation of the eyeball. It can reduce the extent of atherosclerosis or disease. It can alleviate the extent of sciatic nerve injury. It can depress model rats' kidney serous membrane of the invasion and tubular-film thickness to reduce the extent of kidney disease.
The main innovation of this study have four points: First, using the blood stasis blocks collaterals of diabetes pathogenesis theory of traditional Chinese medicine as guidance, which is successful in transplanted Fuangdanshen tablet to the type 2 diabetes therapy, which is effective to reduce the selecting scope of anti-diabetes Chinese medicine. The second is that the new section of the salvianolic acid which can lower blood sugar significantly is found. Third, the invention of this new set of anti-diabetes, which is the salvianolic acid+notoginsenoside+borneol group. Fourth, it was found that the Fufang Danshen category-the lowering blood sugar effect of Fufang danshen diwan, Suxiao Jiuxin pill, Diao xinxuekang capsule.
In short, this study makes a useful attempt to guide the anti-diabetes Chinese medicine selecting by the pathogenesis theory of traditional Chinese medicine, some good signs are found, which is worth going deep into discussion, summing up constantly to establish a new traditional Chinese medicine drug selecting and research and development pattern.
由于1型糖尿病发病率较低,不到5%,而且主要依赖胰岛素治疗,所以本研究主要针对2型糖尿病。
对2型糖尿病的认识半个多世纪以来一直局限在胰岛素分泌不足上,对其治疗自然也就主要集中在促进胰岛细胞对胰岛素的分泌上;药物的研发亦主要集中在胰岛素促泌剂上,导致治疗手段长期相对匮乏。
胰岛素抵抗(Insulin resistance,IR)是胰岛素的外周靶组织对胰岛素的敏感性与反应性降低,从而导致胰岛素难以产生正常的生理效应。研究表明,IR是2型糖尿病发病的关键驱动因素,也是一系列代谢异常,并导致心血管等并发症的核心,是产生糖尿病、冠心病、高血压等疾病的“共同土壤”。因此,针对IR的治疗是治疗2型糖尿病的关键。
由于对2型糖尿病发病机理的认识发生了根本性的转变,从对胰岛细胞本身的分泌功能的重视,转移到对胰岛素抵抗和胰外作用的重视上来,导致药物的研发速度不断加快,通过改善胰岛素抵抗来治疗2型糖尿病的新药便不断问世。
糖尿病属中医的“消渴病”。中医对消渴病的病机认识,自古迄今大都认为是阴津亏损,燥热内盛;医生按照肺、胃、肾三消论治。但自当代施今墨、祝谌予氏创立气阴两虚和瘀血阻络病机学说以来,已被大多数临床医生所接受,极大地推动了对消渴病病机的研究。随后痰、湿、毒致病等各种病机学说被不断地提出,极大地丰富了对消渴病发病机理的认识,使得临床疗效不断提高。由于对消渴病病因病机认识的不断深化,使得近十余年来抗糖尿病中药新药品种从无到有、增长迅猛。据季绍良报道,1985年～1992年未见有申报批准治疗糖尿病的中药新药;1992年～1999年4月,共批准14个;而1999年～2002年已批准临床研究的达到约30个。
但是,目前临床上抗糖尿病药物仍然是以西药为主,中药仍处于辅助地位。究其原因:一是中药新药研发依然沿袭西药新药研发的思路,主要精力都集中在有效成分提纯和药理作用研究上;二是新药处方设计缺乏中医病因病机理论和中药配伍理论的指导,药物筛选局限在古方、验方上;三是新药研发者与临床联系不紧密,研发思路落后于临床实践,对糖尿病的认识仍然局限在阴虚燥热、气阴两虚的病机上,一些病机新理论如:瘀血、痰湿、热毒等,则还没有进入抗糖尿病新药研发者的视野。因此,充分发挥中医药理论的指导作用,针对瘀血、痰湿和热毒等病机新理论,有目标地扩大药物筛选范围,研发疗效确切的抗糖尿病中药新药就是我们的当务之急。
现代中医病机理论认为,气阴两虚——阴虚燥热——阴阳两虚是2型糖尿病发生、发展的基本规律,而“瘀血阻络”则贯穿2型糖尿病的始终。气为血帅,气虚致血行无力;而“阴虚必血滞”,血流缓慢易凝滞血瘀。临床研究表明,2型糖尿病血瘀证与胰岛素抵抗密切相关。临床研究还表明,活血化瘀法对降低血糖和防治并发症均具有显著疗效。
本研究在胰岛素抵抗——“共同土壤说”和瘀血阻络——“共同病机说”的理论启发下,选择复方丹参片类制剂——即具有活血化瘀功效的、常用于治疗冠心病的小复方制剂——作为切入点,针对糖尿病胰岛素抵抗和瘀血阻络这个关键环节,首先对其进行抗糖尿病作用的临床和实验验证,探讨不同类的活血化瘀药物降血糖的可能性,以期能够有目标地拓展抗糖尿病有效部位的筛选范围;然后对其进行拆方研究,筛选有效部位,观察其降低血糖和防治糖尿病慢性并发症的效果,并探讨其作用机制,为下一步进行有效部位重新组方打下基础;并探索一条抗糖尿病中药新药筛选的新途径。
具体研究内容及结果如下:
西医学认为,胰岛素抵抗是2型糖尿病发生发展主要因素,2型糖尿病和冠心病有共同的发病土壤——胰岛素抵抗;中医学认为,瘀血既是糖尿病的病理产物,又是糖尿病发生发展的动因,2型糖尿病和冠心病都有共同的的发病机理——瘀血阻络。据此,我们推测凡是具有活血化淤作用的能够治疗冠心病的中药制剂都有可能用于治疗胰岛素抵抗的2型糖尿病。
首先,我们对活血化瘀法治疗冠心病的代表性中成药——复方丹参片和复方丹参注射液,进行2型糖尿病的临床疗效对照研究,结果表明:复方丹参片和复方丹参注射液均具有一定的降低血糖、增加胰岛素敏感性、改善临床症状的作用;与对照组比较,在消除临床症状、提高胰岛素敏感性方面更胜一筹。
其次,我们根据复方丹参片类制剂(即具有活血化瘀功效的、常用于治疗冠心病的小复方制剂)药味少、活性部位相对明确、研究较为简便的特点,选择了复方丹参滴丸、速效救心丸、地奥心血康胶囊以及复方丹参片与罗格列酮作比较,进行了降血糖的实验验证,发现它们都显示出一定的降血糖效果,同时,都能够提高胰岛素敏感指数;其中复方丹参片效果最好,这为我们下一步的筛选指明了方向。本实验结果充分证明,在中西医理论的指导下,我们可以缩小新药研发的筛选范围,使无目标的撒网式筛选变成有目标的猎取式筛选,取得事半功倍的效果。
第三,我们根据复方丹参片中主要成分性质不同,将其拆分成水溶性部位和脂溶性部位,并进行抗糖尿病的实验研究,发现复方丹参片水溶性部位、脂溶性部位均具有降低血糖、改善胰岛素抵抗的作用,但复方丹参片水溶性部位作用相对较强。
第四、我们将复方丹参片水溶性部位进行进一步拆分和重新组万,并进行抗糖尿病的实验研究,结果显示:除三七皂苷组之外,丹酚酸组、丹酚酸+三七皂苷组、丹酚酸+三七皂苷+冰片组血糖均显著下降。其中,丹酚酸+三七皂苷+冰片的血糖下降幅度最大。我们还发现了丹酚酸类这个具有显著降血糖作用的新部位。
第五、我们对复方丹参片有效部位拆方进行了抗糖尿病作用机理探讨,发现它们能够抑制超氧化物MDA,修复胰腺组织;降低血浆FFA、TNF—α,增强胰岛素受体的敏感性;提高ISR-1、IRS-2和PI3K的表达水平,减轻胰岛素受体后的抵抗;并且降低TG、改善脂肪肝,减少肝糖原的输出;通过以上多环节、多途径、多靶点的作用来达到控制血糖、治疗2型糖尿病的目的。还发现了丹酚酸+三七皂苷+冰片组这一新组方在改善胰岛素抵抗、减轻胰岛细胞损伤、改善脂代谢、抑制脂肪肝等多方面都有明显作用和独特优势,值得进一步的开发研究。
第六,我们的研究还发现,复方丹参片可能通过减少糖尿病大鼠糖基化产物、降低血脂、抑制组织过氧化产物的产生及组织增生来改善2型糖尿病大鼠慢性并发症。病理组织学检查显示,复方丹参片抑制模型大鼠眼球小血管血栓形成的作用极为显著,可改善眼球血液循环;能减轻模型大鼠动脉硬化或病变的程度;减轻模型动物坐骨神经损伤程度;能抑制模型动物肾脏系膜内浆液浸润、肾小管基膜增厚,减轻肾脏病变程度。
本研究的创新之处主要有三点:一是尝试运用中医瘀血阻络的糖尿病病机理论指导,并成功地将复方丹参片类制剂移植到2型糖尿病的治疗上,发现了复方丹参类制剂——复方丹参滴丸、速效救心丸、地奥心血康胶囊都有一定的降血糖作用,有效地缩小了抗糖尿病中药的筛选范围,初步验证了中医瘀血阻络病机理论对抗糖尿病中药筛选的指导意义。二是发现了丹参中的丹酚酸类部位具有明显的降低2型糖尿病模型大鼠血糖的作用。丹酚酸类的降血糖功效在以往的文献中尚未见报道,这是一个令人鼓舞的新发现,说明如果有理论的指导,筛选将更有针对性,筛选的效率会更高。三是我们还发现丹酚酸+三七皂苷+冰片组这一新组方通过改善胰岛素抵抗、减轻胰岛细胞损伤、改善脂代谢、抑制脂肪肝等多个方面作用,达到抗糖尿病的目的,值得进一步的开发研究。
总之,本实验研究对运用中医病机理论指导抗糖尿病药物筛选进行了有益尝试,发现了一些好的苗头,值得我们进行深入探讨,不断总结经验,以期建立一种新的中药新药筛选与研发模式。
Diabetes is a series of metabolic disorder syndrome in protein, fat, water and electrolytes, which due to the interaction of genetic and environmental factors, and causes absolutely or relatively to shortage of insulin secretion and sensitivity decrease of target cells to insulin. Diabetic patients with long-term elevated blood sugar can cause organ damage, which leads to function failure due to the viscera dysfunction. Because of the serious harmfulness of diabetes and the incidence rate increases year by year, coupling with the need for the high cost, which has become the world to face a serious challenge to prevent and therapy diabetes. Likewise, anti-diabetes drugs also have great market prospects, which makes anti-diabetes drugs researched and developed to become one of the focus in the world.
As the incidence of type 1 diabetes is low, less than 5 percent, and mainly relies on insulin therapy, this study is for type 2 diabetes primarily. The knowledge about type 2 diabetes has been confined to the lack of insulin secretion more than half a century, which causes the treatment for it has been focused on promoting insulin secretion agent naturally. Drugs research and development has been focused on promoting insulin secretion agent, leading to the relative lack of long-term treatment.
Insulin resistance (Insulin resistance, IR) is the peripheral insulin target tissues to insulin sensitivity and responsiveness decreases, leading to it is difficult for insulin to produce the normal physiological effects. Research shows that IR is the key driving factor leading to the incidence of type 2 diabetes. It is also a range of metabolic disorders, leading to cardiovascular complications such as the core. It is the "common soil" where diabetes, coronary heart disease and hypertension happen. Therefore, the treatment for IR is the key of treating type 2 diabetes.
Since the awareness about the pathogenesis of type 2 diabetes have changed fundamentally, the attention of which transits from the islet cells their own secretion to the action of IR and outside the pancreas. It leads to drug research and development continuing to accelerate, which causes that it is constantly available to improve insulin resistance to the treatment of type 2 diabetes drugs.
Diabetes belongs to Chinese medicine "wasting-thirst". The awareness about the pathogenesis of "wasting-thirst" has been considered to be the deficiency of body fluid that causes dryness-heat being excessive in the interior. Doctors take the way of treatment for diabetes in accordance with the lung, stomach and kidney. However, since the deficiency of both vital energy and yin and stagnation of blood theory has been founded by Shi jinmo and zhu chenyu this contemporary, which has been accepted by the majority of clinicians. It drives enormously to have research on the pathogenesis of diabetes. Subsequently, sputum, humid, and harm as such pathogenesis theories were constantly raised, greatly enriching the awareness on the pathogenesis of diabetes, which makes therapeutic effect continue to increase. The awareness for pathogeny and pathogenesis of "wasting-thirst" has deepened constantly, which makes anti-diabetes drugs varieties of Chinese medicine from scratch to rapid growth in nearly past 10 years. According to the report by Ji shoaling, the approval of new Chinese medicine treatment of diabetes drug have not been declared from 1985 to 1992; 14 had been approved from 1992 to April 1999; while about 30 had been approved to have clinical research from 1999 to 2002. However, the current clinical anti-diabetes drug is still mainly western medicine, Chinese medicine is still in secondary status. The reasons: First, traditional Chinese medicine research and development of new drugs continues to follow the thinking of western medicine research, the main efforts are concentrated on active ingredients purification and research on the pharmacological effects; Second, the design of new Chinese medicine prescription lacks guiding of pathogeny and pathogenesis theory of Chinese medicine and Chinese medicine compatibility theories, drugs selecting confined to the ancient prescription and experimental prescription. Third, the researchers of new drugs are not closely associated with the clinic, the ideas of research and development drop behind the clinical practice. The awareness of diabetes is still confined to the pathogenesis of deficiency of yin feverish sensation and deficiency of both vital energy and yin. Some new theories of pathogenesis such as blood stasis, phlegmatic hygrosis, pyretic toxicity have not enter into the the vision of the anti-diabetes drug researchers. Therefore, it is urgent to take full advantage of the guiding of Chinese medicine theory, for the new pathogenesis theory of blood stasis, phlegmatic hygrosis, pyretic toxicity, expanding the scope of drugs selected with aim, researching and developmenting certain effect of the anti-diabetes drug Chinese medicine.
The pathogenesis of modern traditional Chinese medicine theory considers that deficiency of both vital energy yin-deficiency of yin feverish sensation-simultaneous asthenia of yin and yang is the basic rule for the occurrence and development of the type 2 diabetes, while the blocking collaterals of blood stasis traverses from the beginning and the end of type 2 diabetes. Qi is the commander of blood, the deficiency of qi causing it incapable to circulate, while deficiency of yin must cause blood stasis, slow flow blood easily leads to blood stagnation. Clinical studies show that blood stasis of type 2 diabetes is closely related to insulin resistance. They also show that it is significantly effective to lower blood sugar and prevent complications for activating blood to resolve stasis treatment.
This study is inspired by the theory of insulin resistance- the "common soil" and blood stasis blocks collaterals-"common pathogenesis theory", selecting compound Danshen tablet generic medicine, that is, it has the effect of activating blood to resolve stasis and the small compound preparation which is often used to therapy coronary heart disease - as a point of penetration. Facing the key link of insulin resistance and blood stasis blocks collaterals, first of all its anti-diabetic role of the clinical and experimental verification, discussing the possibility of lowering blood sugar about different types of activating blood to resolve stasis drugs, expecting to develop the selected scope of anti-diabetic effective parts with aim. Then demolition research has been done and the effective parts are selected. Observing the effect of its lowering blood sugar and prevent chronic complications of diabetes, discussing its mechanism, which lays the foundation to form medicine over again about effective parts for the next step. To explore a new way of selecting anti-diabetes Chinese medicine.
Modern medicine considers that insulin resistance is the major factor which causes type 2 diabetes to start and develop. Type 2 diabetes and coronary heart disease have a common soil - insulin resistance. Traditional Chinese Medicine considers that blood stasis is not only the pathology production of diabetes, but also is the agent of the occurrence and development of diabetes. Type 2 diabetes and coronary heart disease have a common pathogenesis- blood stasis blocks collaterals. Accordingly, we speculate that any Chinese medicine formulations relieving blood stasis role can therapy coronary heart disease, which may also be used for the treatment of type 2 diabetes caused by insulin resistance.
First of all, we have a control research on the clinical efficacy of type 2 diabetes about the representative Chinese medicines to therapy coronary heart disease which can relieve blood stasis-compound Danshen tablet and compound Danshen injection. The results indicate that compound Danshen tablet and compound Danshen injection can lower blood sugar, increase insulin sensitivity and improve the clinical symptoms in a way. They are superior to the control group in the elimination of clinical symptoms and improvement of insulin sensitivity.
Secondly, due to these Chinese medicine are made up of a few ingredients, relatively clear active parts, so we choose Fufang danshen diwan, Suxiao jiuxin wan, Diao xinxuekang capsule and Fufang danshen tablet to compare with Rosiglitazone, and have experimental verification of lowering blood sugar, which showed that they all show some certain effect of lowering blood sugar. At the same time, they all can improve insulin sensitivity index. Among them, Fufangdanshen tablet is the best, which points out the direction t for our selecting of the next step. The results of this study fully demonstrate that under the guidance of traditional Chinese medicine, we can take the effect of getting twice the result with half the effort, by narrowing the selection scope of new drug research and development, which makes no goal-selecting of the nets become the hunt for selecting with aim.
Third, due to the major components of a different nature in Fufang danshen tablet, it is split into water-soluble part and fat-soluble part, the experimental anti-diabetes research is done. It is found that both water-soluble part and fat-soluble part of Fufang danshen tablet can lower blood sugar and improve insulin resistance, but the action of water-soluble part is relatively stronger than that fat-soluble part.
Fourth, water-soluble part of Fufang danshen tablet is further split into and re-group and the experimental research is conducted on the anti-diabetes. The results show that blood sugar decreases significantly in the salvianolic acid group, the salvianolic acid+ notoginsenoside group and the salvianolic acid+ notoginsenoside+ borneol group in addition to notoginsenoside group. Among them, blood sugar of the salvianolic acid+ notoginsenoside+ borneol group decreases most severely. We also find that the new section of the salvianolic acid which can lower blood sugar significantly.
Fifth, the mechanism of anti-diabetes is discussed by splitting the effective parts of Fufang danshen tablet. It is found that they can depress superoxide dismutase MDA and repair pancreatic tissue. They can reduce plasma FFA, TNF-α, enhance the sensitivity of insulin receptors. They can improve the expression of ISR-1, IRS-2 and PI3K and reduce the insulin resistance. They also lower TG, improve fatty liver and reduce the output of liver glycogen. It is the aim to control blood sugar and therapy type 2 diabetes by much more links, multi-channel and multi-role target. It is also found that the new group medicine of the salvianolic acid+ notoginsenoside+ borneol group has obvious role and unique advantages in improving insulin resistance, reducing the islet cell damage and improving fat metabolism and depressing fatty liver, which is worth the further development of research.
Sixth, the study also found that maybe Fufang danshen tablet improves the proliferation of type 2 diabetic rats' chronic complications by reducing the glycosylation product, lowering blood fat and depressing organized suppression of the product produced. Pathological examination reveals that the action of depressing the model rats' small vascular thrombosis in the eyeball is extremely significant for Fufang danshen tablet, which can improve blood circulation of the eyeball. It can reduce the extent of atherosclerosis or disease. It can alleviate the extent of sciatic nerve injury. It can depress model rats' kidney serous membrane of the invasion and tubular-film thickness to reduce the extent of kidney disease.
The main innovation of this study have four points: First, using the blood stasis blocks collaterals of diabetes pathogenesis theory of traditional Chinese medicine as guidance, which is successful in transplanted Fuangdanshen tablet to the type 2 diabetes therapy, which is effective to reduce the selecting scope of anti-diabetes Chinese medicine. The second is that the new section of the salvianolic acid which can lower blood sugar significantly is found. Third, the invention of this new set of anti-diabetes, which is the salvianolic acid+notoginsenoside+borneol group. Fourth, it was found that the Fufang Danshen category-the lowering blood sugar effect of Fufang danshen diwan, Suxiao Jiuxin pill, Diao xinxuekang capsule.
In short, this study makes a useful attempt to guide the anti-diabetes Chinese medicine selecting by the pathogenesis theory of traditional Chinese medicine, some good signs are found, which is worth going deep into discussion, summing up constantly to establish a new traditional Chinese medicine drug selecting and research and development pattern.
引文
[1]刘曦婷.糖尿病的中药治疗[J].天津药学,2002,14(5):11.
[2]李秀钧,钱荣立.胰岛素抵抗及其临床意义[J].中国糖尿病杂志,1999,7(3):163.
[3]季绍良,陈易新.中药新药的分类与选题立项[J].中国中医药信息杂志,2000,7(1):14.
[4]张延群.消渴病定义及辨证分型规范化探讨[J].山东中医学院学报,1995,19(1):25-27.
[5]魏军平.62例糖尿病患者血液流变学观察[J].辽宁中医杂志,1993,11(8):29.
[6]梁晓春,郭赛珊,王香定.糖尿病患者血浆TXB2、6—keto—POFia水平、全血粘度与血瘀证及微血管病的关系[J].中西医结合杂志,1992(5):297-299.
[7]顾士芬.糖尿病患者甲皱微循环观察[J].江苏医药,19911(5):15-17.
[8]马秀华.107例Ⅰ糖尿病患者之甲皱微循环观察[J].中西医结台杂志,1985,20(10):633.
[9]祝谌予.用活血化瘀法为主治疗糖尿病病例报告[J].新医药学杂志,1978,10(5):8-9.
[10]詹锐文.第四届全国糖尿病(消渴病)学术研讨会论文集[M].284页.
[11]郭赛珊.益气养阴活血方治疗糖尿病人的舌质和全血粘度的变化[J].中医杂志,1989,8(2)33-34.
[12]祝倩.活血化瘀法治疗糖尿病的地位和作用[J].陕西中医,2006,27(3):451-453.
[13]熊曼琪,范冠杰,朱章志,等.胰岛素抵抗的研究思路[J].新中医2000,32(8):44-45.
[14]李秀均.胰岛素抵抗与胰岛素抵抗综合征研究展望[J].中华内分泌代谢杂志,2000,16(5):274-276.
[15]熊曼琪,朱章志.中医中药治疗非胰岛素依赖型糖尿病必须研究胰岛素抵抗[J].中医杂志,1995,36(1):47.
16]Haffner SM,D,Agostino R,Mykkanen L.Insulin sensitivity in subjects with t ype 2 diabetes[J].Diabetes Care,1999,22:562-568.
[17]Jia WP,Xiang KS,Chen L,et al.Epidemiologic study on metabolic syndrom e in mormal and overweight Chinese in SHANGHAI[J].Diabetes,2000(suppl 1),49:A184.
[18]Lyon C,Law R,Hsueh W.Adiposity,inflammation,and athero---genesis[J].E ndocrinology,2003,144:2195-2200.
[19]张光珍,孙福庆,娄秀舜,等.中心型肥胖与胰岛素抵抗2型糖尿病相关性探讨[J].辽宁实用糖尿病杂志,2001,9(2):25.
[20]陈伟,向红丁.游离脂肪酸在胰岛素抵抗和2型糖尿病发生中的作用[J].中国临床营养杂志.2003,11(3):223.
[21]周红文.脂肪组织的内分泌功能[J].国外医学内分泌学分册,2002,22(1):34.
[22]Szanto.L.Kahn CR.Selecti-ve interaction between 1-eptin and insulin signali ng pathways in a hepatic cell line[J].Proc Natl Acad Sei USA.2000,97(5):2355.
[23]陈慧玲,谢志东,雷闽湘,等.2型糖尿病患者血浆TNF—α水平与胰岛素抵抗的关系[J].中国医师杂志,2003,5(10):1358.
[24]刘瑞,白怀,刘秉文,等.胰岛素受体信号传导[J].生理科学进展,2001,32(3):254-256.
[25]Whitehead JP,Humphreys P,Krook,et al.Molecular scanning of the ins ulin receptor substratel gene in subjects with severe insulin resistance[J].Diabetes,1988,47:837.
[26]余峰彬,于红.代谢综合征分子机制研究进展[J].天津医药,2005,33(7):470.
[27]石海燕,马臻,董砚虎.胰岛素抵抗的分子机制研究进展——第62届美国糖尿病协会年会侧记.国外医学内分泌学分册,2003,4(23):65-66.
[28]沈稚舟,吴松华,邵福源,等.糖尿病慢性并发症[M].上海:上海医科大学出版社,1999:1476-1479.
[29]叶山东,朱禧星.临床糖尿病学.安徽:安徽科学技术出版社,2005:202-204.
[30]Kunsch C,Medford RM.Oxidative stress as a regulator of gene ex—pression in the vasculature.Circ Res,1999,85:753-766.
[31]王薇,谢自敬,阿依努尔 阿布力克木·吐尔地,等.2型糖尿病患者氧化应激状况及影响因素分析[J].中国糖尿病杂志,2007,8(15):487-489.
[32]MaserelB.OuedrangoR,DegneJM[J].EudMed Chem,1997,32(5):453.
[33]庄祥云.2型糖尿病治疗的进展[J].日本医学介绍,2001,22(1):33.
[34]常宝成.胰岛素增敏剂——罗格列酮在糖尿病中的应用[J].国外医学内分泌学,2001,21:35.
[35]王宪,高孝斗,许华强,等.拜糖平治疗2型糖尿病的临床观察[J].中原医刊,2001,29(2):22.
[36]李妍,苏乐群.胰岛素抵抗的药物治疗[J].山东医药工业,2001,1(20):26-28.
[37]Yavuz D,Koc M,Topmk A,et al.Efects of ACE inhibition and AT1-recept oran tagonism on endothelial function and insulin sensitivity in essential hype sensiv e atients[J].J Renin Angiotensin Aldosterone Syst,2003,4(3):197-203.
[38]Howlett KF,W att MJ,Hargreaves M,el al.Regulation of glucose kinetics during itense exercise in humans:efects of alpha-and betaadrenergicblockade[J].Met abolism,2003,52(12):1615-1620.
[39]沈稚舟,吴松华,邵福源,等.糖尿病慢性并发症.上海:上海医科大学出版社,1999:1024-1027.
[40]叶山东,朱禧星.临床糖尿病学.安徽:安徽科学技术出版社,2005:177-181.
[41]李以肚.成年病治疗药的开发概况(续)国外医药一台成药、生化药、制剂分册,1995.16(1):20.
[42]赵晶,戴德哉.糖尿病并发症的药物治疗.药学进展,2003,27(2):88-91.
[43]Reynolds lames EF Mardnda[e the ext T～pharmacopoeia 31st ed London:Ph～aaceutical Press.1996:342.
[44]彭亚贞,史玉曼.糖尿病并发症治疗的成功和失败经验[J].医药工业科研开发信息,1998,(1):36.
[45]Pieper G M,Langenstroer P,SiebeneichW.Diabetic-inducedendoth elial dysfun ction in rat aorta:role of hydroxyl radicals[J].Card/ovasc Res,1997,34(1):145-156.
[46]陈长青,熊曼琪,李赛美,等.消渴病(糖尿病)的病机研究进展[J].中国中医基础医学杂志,2002,8(10):72-73.
[47]熊曼琪.脾虚是消渴病的重要病机[J].广州中医学院学报,1991,(7):13-14.
[48]潘朝曦.糖尿病病因、病机、治法新探[J].江苏中医,2000,21(1):1-3.
[49]陈汉桥.肝气郁结与消渴病关系的理论研究[J].江苏中医,1997,18(9):49-50.
[50]邹如政.糖尿病从肝论治[J].中国医药学报,1998,13(1):17-23.
[51]张鸿恩.糖尿病中医病机探讨[J].吉林中医药,1989,(1):11-12.
[52]周叔平.试论糖尿病气虚为本[J].新中医,1999,31(2):5-6.(1):25-27.
[53]曹忠贞.论消渴与痰[J].中医药研究,1997,13(2):8-9.
[54]金学仁.略论糖尿病与湿[J].江南中医,1993,(1):6-7.
[55]徐正正.不同病程糖尿病患者的征候特征[J].中医杂志,200,41(1):44-45
[56]王如沾.论毒与糖尿病[J].山东中医杂志,1999,18(8):339-341.8-9.
[57]魏军平.62例糖尿病患者血液流变学观察[J].辽宁中医杂志,1993,11(8):29
[58]梁晓春,郭赛珊,王香定.糖尿病患者血浆TXB2、6-keto-PGF-la水平、全血粘度与血瘀证及微血管病的关系[J].中西医结合杂志,1992(5):297-299.
[59]顾士芬.糖尿病患者甲皱微循环观察[J].江苏医药,19911(5):15-17.
[60]王柏生.糖尿病患者血液流变学和甲皱微循环的改变[J].临床医学,1987(2):95-99.
[61]俞亚琴,王彬.从血瘀角度探讨Ⅱ型糖尿病胰岛素抵抗[J].浙江中医杂志,2002:175-176.
[62]何晓兰.活血化瘀法治疗老年糖尿病54例[J].辽宁中医杂志,1996;(4):16.
[63]王开锋.水蛭三黄汤治疗糖尿病20例临床分析[J].湖南中医杂志,1993,6(9):2-4.
[64]祁松强.从瘀论治糖尿病[J].实用中西医杂志,1996,8(9):493-495.
[65]李惠林,熊曼琪,邓尚平,等.加味桃核承气汤对实验性糖尿病大鼠胰岛素受体的影响[J].中国中西医结合杂志,1995,15:338-340.
[66]鲁瑾,邹大进,张家庆,等.黄芪预防肿瘤坏死因子—2所致胰岛素抵抗[J].中国中西结合杂志,1999,19(7):420.
[67]王凌,李秋贵,浦信行,等.参地降糖颗粒对高果糖大鼠胰岛素抵抗的影响[J].中医杂志,2001,42(11):686.
[68]钱东生.山茱萸乙醇提取液对NIDDN大鼠骨骼肌GLUT4表达影响的实验研究[J].中国中药杂志,2001,26(12):85.
[69]李宗友.胡芦巴抗糖尿病和降胆固醇作用[J].国外医学中医中药分册,1999,21(4):9-13.
[70]李真,马高峰.生地黄连液对四氧嘧啶小鼠影响的实验研究[J].辽宁中医杂志,2000,27(12):573-574.
[70]宋福印.消渴停对胰岛8细胞凋亡及相关基因Bcl-2,Fas蛋白表达的影响[J].中国中医药信息杂志,2001,8(6):24.
[72]尚文斌,金妙方,方泰惠,等.糖渴清降血糖机制的实验研究[J].中药药理与临床,1996,(4):31-33.
[73]张冰,高光艳,江佩芬.菊苣胶囊对小鼠血糖水平的影响[J].北京中医药大学学报,1999,22(1):28-30.
[74]沈忠明,李英,姜宏.降糖中药对a-葡萄糖苷酶抑制作用的研究[J].中国生化药物杂志,2000,21(2):69-70.
[75]梁晓春,郭赛珊,王香定,等.金芪降糖片治疗气阴两虚火旺型糖尿病临床及实验研究[J].中国中西医结合杂志,1993.13(10):587.
[76]季绍良,陈易新.中药新药的分类与选题立项[J].中国中医药信息杂志,2000,7(1):14.
[77]周华容,钟国跃.浅析糖尿病中成药的开发[J].世界科学技术—中医药现代化(思路与方法),2003,5(5):18-23.
[78]魏子孝.立足医疗实际对糖尿病中药新药开发的思考[J].中国现代临床医学,2004,3(11):39-40.
[79]李天庆,崔听,张志军,等.汉方药治疗糖尿病及其并发症的研究[J].国外医药·中医中药分册,1997,19(6):3-7.
[80]陈广耀.抗糖尿病中药开发前景展望[J].中国新药杂志,2000,9(7):448-451.
[81]王启慧.糖尿病单味中药作用机制研究概述[J].安徽中医学院学报,1999,18(4):58-59.
[82]洪浩.中药降血糖作用机制实验研究进展[J].安徽中医学院学报,2001,20(2):59-61.
[83]曹勇.中医药降糖机理及免疫调节[J].中医药学报,1994,22(1):9-12.
[84]郭舜民,郭尧惠.天然药降血糖成分的研究进展[J].海峡药学,2000,12(10):1-5.
[85]魏子孝.试谈“辨病与辨证相结合”的中医治疗思路模式[J].中华临床医学杂志,2006,37(3):87-89.
[86]陈长青.消渴病(糖尿病)病机探讨—附32例病例报告[J].中医药研究.1997,13(5):4-6.
[87]柴佩芳,胡德培,陈灏珠,等.糖尿病合并心脑血管疾病的多种因素[J].上海医科大学学报,1998,25(3):240.
[88]李正喜.复方丹参片治疗老年性心脑血管病133例疗效观察[J].贵州医药,1989,13(2):121-122.
[89]张翼鹿.复方丹参片治疗颅脑外伤后神衰综合症122例[J].云南中医杂志,1984,5(5):24-26.
[90]魏德新.克朗宁并复方丹参片治疗脂肪肝49例[J].中国中西医结合杂志2000:20(10):78-789.
[91]周幼龙.非诺贝特片及复丹参片治疗脂肪肝156～J疗效观察[J].山西临床医药,2002,11(6):438-439.
[92]孔武明,龚均,董蕾.复方丹参片联合维生素E对慢性乙型肝炎肝纤维化的影响研究[J].中国实用内科杂志,2005,25(9):799-801.
[93]孙权.促肝细胞生长素联合复方丹参片治疗肝硬变腹水32例[J].中西医结合杂志,1998增刊(下):165.
[94]成娟.肝苏颗粒联合复方丹参片治疗肝纤维化28例[J].江西中医学院学报,2000:12(3):7.
[95]谭孝.硝苯地平和复方丹参片治疗老年高血压临床分析[J].中国现代医学杂志, 1998:8(6):69-70.
[96]洪梅.复方丹参片治疗恢复期妊高征疗效观察[J].河南实用神经杂志,2002:5(2):66.
[97]曹银娥.复方丹参片治疗老年皮肤瘙痒症[J].山东医药,1997:37(8):62-63.
[98]张青文,刘奇莉.复方丹参片治疗胃肠痉挛性腹痛[J].中国乡村医药.
[99]李立东.复方丹参片治疗Colles骨折疗效观察[J].交通医学,1999:13(1):120.
[100]倪秀英,郑荣.复方丹参片治疗Ⅰ型慢性精神分裂症效果观察[J].海峡药学,2001:13(4):31.
[101]梅全喜.复方丹参片的新用途.家庭中医药,2002,12(9):52.
[102]宋怀方,林令华.复方丹参片对糖尿病人超氧化物歧化酶活力及血液流变学的影响[J][J].药学进展,2000,24(3):170-172.
[103]王筠默.复方丹参片的药理作用研究[J].中成药研究,1984,(11):22-24.
[104]于培兰.丹参对小鼠耐急性重复性缺氧能力形成的[J].首都医科大学学报,2001:22(1):65-66.
[105]潘文军.复方丹参片对家兔实验性心肌梗塞和心肌酶谱的影响[J].沈阳药科大学学报 2005,22(1):53-55.
[106]高秀梅.复方丹参方抗大鼠心肌缺血作用[J].天津中医药,2003:(1):23-42.
[107]张昱.复方丹参片对大鼠心肌缺血再灌注损伤的保护[J].河南中医药学刊,1997:12(6):15-17.
[108]范照冬.复方丹参片对大鼠实验性脑缺血的保护作用研究[J].山西职工医学院学报,2000,10(2):3-4.
[109]朱永林.复方丹参片对慢性脑缺血大鼠脑内HIF-1α表达的影响[J].实用神经疾病杂志,2005,8(5):18-19.
[110]屈彩琴.复方丹参片对大鼠实验性血栓形成的[J].河北中医,1999,21(4):252.
[111]覃仁安.复方丹参片对阿尔茨海默病大鼠脑内氨基酸类神经递质含量的影响[J].中草药,2004,35(8):905-908.
[112]覃仁安.复方丹参片对阿尔茨海默病大鼠学习记忆障碍和脑组织β-AP含量的影响[J].中华中医药杂志,2005,20(6):377-378.
[113]杨桂珍,黄科军.复方丹参片对糖尿病大鼠坐骨神经和红细胞山梨醇浓度的影响[J].中国老年学杂志,2007,27(1):33-34.
[114]杨桂珍,吴莉.复方丹参片对实验性糖尿病大鼠LP0含量及SOD水平的影响[J].陕西中医,2007,28(3):372-374.
[115]郑虎占,董泽宏,祭靖.中药现代研究与应用.第2卷.北京:学苑出版社.1997.10.
[116]林佳,徐丽珍,李琰,等.不同产地丹参中丹参酮Ⅱ_A的含量比较[J].中国中药学杂志,2002,27(2):153-154.
[117]孙学刚,贾钰华,陈育鹩.定心方及丹参酮对血小板膜粘附分子表达的影响[J].山东中医药大学学报,2001,25(1):61-63.
[118]姜开余,阮长耿,陈振纶,等.丹参酮ⅡA磺酸钠对内皮细胞和血小板体外表达粘附分子的作用[J].中国药理学报,1998,19(1):47-50.
[119]吴平生,梁欣伟,郭志刚,等.丹参酮ⅡA抑制血管合成醛固酮及醛固酮合成酶基因CYP11B2信使核糖核酸表达[J].中国循环杂志,1998,13(3):175-177.
[120]费丽萍,李进禧,郑道声,等.丹参酮ⅡA磺酸钠对红细胞内游离钙浓度的影响[J].微循环学杂志,1997,7(4):17-19.
[121]斐文芬,孔德虎,鄢顺勤,等.丹参酮Ⅱ—A豚鼠交感椎前神经节细胞膜电位的影响[J].安徽中医学院学报,1996,15(4):55-56.
[122]赵燕,江文,侯京武,等.钙过负荷和丹参酮对线粒体脂质过氧化影响[J].生物化学与生物物理学报,1995,27(6):610.
[123]王军,邱玉兰.丹参酮对实验性脑梗塞大鼠血液发光学的影响[J].中药药理与临床,1999,15(4):29-30.
[124]徐罗玲,吴琦,王佰瑶,等.丹参酮对人中性粒细胞氧自由基释放的抑制效应[J].中国病理生理杂志,1994,10(6):635-638.
[125]钟先阳,罗仁,魏华.丹参酮ⅡA对大鼠出血性休克再灌注肾损伤的保护作用[J].辽宁中医杂志,2002,29(8):505-506.
[126]钟先阳,罗仁,魏连波.丹参酮ⅡA对大鼠出血性休克一再灌注肾损伤的防治作用[J].中国中西医结合肾病杂志,2002,3(1):13-15.
[127]何丽娜,扬军,姜怡,等.丹参酮对培养PCL2细胞损伤的保护作用[J].中国中药杂志,2001,26(6):413-416.
[128]何丽娜,何素冰,扬军.丹参酮对氯化钾及N-甲基-D-门冬氨酸诱导PCL2细胞钙超载损伤的保护作用[J].中国现代应用药学杂志,2001,18(3):179-181.
[129]何素冰,何丽娜,扬军.丹参酮对大鼠皮层神经细胞钙超载损伤的保护作用[J].中成药,2002,24(5):371-373.
[130]吴世蓉.不同产地丹参其主要化学成分的分离与测定[J].基层中药杂志,2002,16(3):24.
[131]黄诒林,张均田.丹参中三种水溶性成分的体外抗氧化作用[J].药学学报,1992,27(2):96-100.
[132]李静,何丽一,宋万志.丹参中水溶性酚酸类成分的薄层扫描测定法[J].药学学报,1993,28(7):543-547.
[133]桂冠华.张均田.丹酚酸A对钠钾ATP酶活性及基因表达的影响[J].中国病理 生理杂志,1998,14(7):862.
[134]王洁.张均田.总丹酚酸抗脑缺血与抗血栓的关系[J].中国药理学通报,1999,15:204-206.
[135]王浩,张均田.总丹酚酸的抗脑缺血和抑制谷氨酸释放作用[J].中国药理学与毒理学杂志,1999,15:164:166.
[136]YokozawaT.LeTw.Efectofmagnesiumlithospermate B on the renal and urinary kallikrein activities in rats with adenine·induced renal failure[J].Nippon J Jnzo Gak kai Shi 1993.35:337-342.
[137]Yokozawa T,Yasui T,Oura H.Molecular biological analysis of the effects o f ginsenoside -Rb2 on albumin mRNA in streptozotoci-ninduced diabetic rats[J].JPh arm Pharmacol,1996,48:763-767.
[138]Kenarova B,Neychev H,Hadjiivanova C,et al.Immunomodulating activity of ginsenoside Rg1 from Panaxginseng[J].Jpn J Pharmacol,1990,54:447-454.
[139]Zhang HG,Li XH,Yang ZC.Effects of Panax notoginseng on myocardial Gs a mRNA expression and ATPase activity after severe cald in rats[J].Burns,2003,29:541-546.
[140]林曙光.三七皂苷对高脂血清所致的培养主动脉平滑肌细胞增殖的作用[J].中国药理学报,1993,14(4):314-316.
[141]张林波,杨贵贞.三七皂甙Rg1纹状体内注射对帕金森病模型大鼠免疫炎症损伤的拮抗效应[J].中国免疫学杂志,2004,20(2):121-123.
[142]武杰雄,孙家均.PNS、维拉帕米、去甲肾上腺素对大鼠和家兔脑循环的作用比较[J].中国药理学报,1992,13(6):520-523.
[143]Hua JA,Hu WY,Sun ZH.Effect of Panax notoginseng Saponin on Ca2+,CaM in craniocerebral injury[J].Chinese Journal of Integrated Traditional and West em Medicine,1999,19:227-229.
[144]邹玉安,魏阿平.三七皂苷对大鼠缺血脑组织呈氧化氮表达的影响[J].脑与神经疾病杂志,2000,8(4):196-200.
[145]Zhang GQ,Ye RG,Kong QY,et al.Panax notoginseng saponins induced of human renal interstitial fibroblasts and its mechanisms[J].Chinese Journal of Nephr ology,1998,14:93-95.
[146]刘启德,梁美蓉,陈芝喜,等.冰片对庆大霉素透血脑屏障的影响[J].广州中医学院学报,1994,11(1):37-40.
[147]黎新荣,徐伟,冯毅凡,等.冰片及薄荷醇对尼群地平在家兔体内吸收的影响[J].中国医院药学杂志,2001,21(5):264-266.
[148]王原,吴伟康,黄志宏,等.冰片在正常人皮肤增加曲安缩松的透皮生物利用度[J].中药药理与临床,1992,8(特辑):178.
[149]王晖,许卫铭,王宗锐,等.薄荷醇与冰片的促透作用[J].中草药,1997.28(2):93-95.
[150]朱健平,王宗锐,吴宋夏.龙脑促进药物经皮渗透作用的研究[J].中国药学杂志,1999,34(2):104-106.
[151]江文德,徐端正,胡国钧,等.冠心苏合丸的药理研究及其简化制剂—苏冰滴丸的理论基础[J].药学学报,1979,14(11):655-60.
[152]邓文龙.开窍方药的临床及实验研究进展[J].中成药研究,1985,(3)133-38.
[153]江光池,冯旭军,黄岚,等.龙脑和异龙脑对小鼠和家兔的药理作用[J].华西药学杂志,1989,4(1):23-25.
[154]江光池,杨胜华,冯旭军.龙脑和异龙脑的抗炎作用[J].华西药学杂志,1990,5(3):190-191.
[155]叶任高,主编.内科学[M].第5版.北京:人民卫生出版社,2000,798-810.
[156]卫生部.1996～2000国家糖尿病防治规划纲要[J].中国公共卫生管理,1997,13:149.
[157]李光伟,潘孝仁.测人群瞳岛索敏感性的一项新指标[J].中华内科杂志,1993,32(10):655.
[158]黄松.糖尿病动物模型研究现状及进展[J].广西医学,2002,24(1):46-48.
[159]杨竹林,伍汉文,周智广,等.完全弗氏佐剂预防NOD鼠胰岛炎和糖尿病的机理研究[J].中华内分泌代谢杂志,1999,15(5):2713.
[160]郑里祥.STZ和Alloxan联合使用复制实验性糖尿病大鼠模型[J].中国病理生理杂志,1999,15(8):758.
[161]都健,赵玉岩,谢辉,赵谨.喂养型胰岛素抵抗动物模型的建立与评价[J].中国医科大学学报,2002,31(5):343.
[162]司晓晨,尚文斌,卞慧敏,等.链脲佐菌素加高脂膳食诱导2型糖尿病大鼠模型[J].安徽中医临床杂志,2003,15(5):383.
[163]蔡文就,熊曼琪,朱章志,等.实验性NIDDM大鼠模型及其胰岛素抵抗的初步研究[J].广州中医药大学学报,1997,14(2):87.
[164]霍建新,唐静晓.郭永强.药物治疗糖尿病性视网膜病变的现状[J].包头医学院学院,2003,4(1):236-237.
[165]张军,王凤云,肖凤霞.丹参药材提取液中丹参酚酸大孔树脂吸附工艺研究[J].中药新药与临床药理,2005,12(3):263-265.
[166]刘睿,高巨,王春红,等.G-821树脂提取三七叶皂苷的工艺研究[J].中草药,2007,38(7):1026-1028.
[2]李秀钧,钱荣立.胰岛素抵抗及其临床意义[J].中国糖尿病杂志,1999,7(3):163.
[3]季绍良,陈易新.中药新药的分类与选题立项[J].中国中医药信息杂志,2000,7(1):14.
[4]张延群.消渴病定义及辨证分型规范化探讨[J].山东中医学院学报,1995,19(1):25-27.
[5]魏军平.62例糖尿病患者血液流变学观察[J].辽宁中医杂志,1993,11(8):29.
[6]梁晓春,郭赛珊,王香定.糖尿病患者血浆TXB2、6—keto—POFia水平、全血粘度与血瘀证及微血管病的关系[J].中西医结合杂志,1992(5):297-299.
[7]顾士芬.糖尿病患者甲皱微循环观察[J].江苏医药,19911(5):15-17.
[8]马秀华.107例Ⅰ糖尿病患者之甲皱微循环观察[J].中西医结台杂志,1985,20(10):633.
[9]祝谌予.用活血化瘀法为主治疗糖尿病病例报告[J].新医药学杂志,1978,10(5):8-9.
[10]詹锐文.第四届全国糖尿病(消渴病)学术研讨会论文集[M].284页.
[11]郭赛珊.益气养阴活血方治疗糖尿病人的舌质和全血粘度的变化[J].中医杂志,1989,8(2)33-34.
[12]祝倩.活血化瘀法治疗糖尿病的地位和作用[J].陕西中医,2006,27(3):451-453.
[13]熊曼琪,范冠杰,朱章志,等.胰岛素抵抗的研究思路[J].新中医2000,32(8):44-45.
[14]李秀均.胰岛素抵抗与胰岛素抵抗综合征研究展望[J].中华内分泌代谢杂志,2000,16(5):274-276.
[15]熊曼琪,朱章志.中医中药治疗非胰岛素依赖型糖尿病必须研究胰岛素抵抗[J].中医杂志,1995,36(1):47.
16]Haffner SM,D,Agostino R,Mykkanen L.Insulin sensitivity in subjects with t ype 2 diabetes[J].Diabetes Care,1999,22:562-568.
[17]Jia WP,Xiang KS,Chen L,et al.Epidemiologic study on metabolic syndrom e in mormal and overweight Chinese in SHANGHAI[J].Diabetes,2000(suppl 1),49:A184.
[18]Lyon C,Law R,Hsueh W.Adiposity,inflammation,and athero---genesis[J].E ndocrinology,2003,144:2195-2200.
[19]张光珍,孙福庆,娄秀舜,等.中心型肥胖与胰岛素抵抗2型糖尿病相关性探讨[J].辽宁实用糖尿病杂志,2001,9(2):25.
[20]陈伟,向红丁.游离脂肪酸在胰岛素抵抗和2型糖尿病发生中的作用[J].中国临床营养杂志.2003,11(3):223.
[21]周红文.脂肪组织的内分泌功能[J].国外医学内分泌学分册,2002,22(1):34.
[22]Szanto.L.Kahn CR.Selecti-ve interaction between 1-eptin and insulin signali ng pathways in a hepatic cell line[J].Proc Natl Acad Sei USA.2000,97(5):2355.
[23]陈慧玲,谢志东,雷闽湘,等.2型糖尿病患者血浆TNF—α水平与胰岛素抵抗的关系[J].中国医师杂志,2003,5(10):1358.
[24]刘瑞,白怀,刘秉文,等.胰岛素受体信号传导[J].生理科学进展,2001,32(3):254-256.
[25]Whitehead JP,Humphreys P,Krook,et al.Molecular scanning of the ins ulin receptor substratel gene in subjects with severe insulin resistance[J].Diabetes,1988,47:837.
[26]余峰彬,于红.代谢综合征分子机制研究进展[J].天津医药,2005,33(7):470.
[27]石海燕,马臻,董砚虎.胰岛素抵抗的分子机制研究进展——第62届美国糖尿病协会年会侧记.国外医学内分泌学分册,2003,4(23):65-66.
[28]沈稚舟,吴松华,邵福源,等.糖尿病慢性并发症[M].上海:上海医科大学出版社,1999:1476-1479.
[29]叶山东,朱禧星.临床糖尿病学.安徽:安徽科学技术出版社,2005:202-204.
[30]Kunsch C,Medford RM.Oxidative stress as a regulator of gene ex—pression in the vasculature.Circ Res,1999,85:753-766.
[31]王薇,谢自敬,阿依努尔 阿布力克木·吐尔地,等.2型糖尿病患者氧化应激状况及影响因素分析[J].中国糖尿病杂志,2007,8(15):487-489.
[32]MaserelB.OuedrangoR,DegneJM[J].EudMed Chem,1997,32(5):453.
[33]庄祥云.2型糖尿病治疗的进展[J].日本医学介绍,2001,22(1):33.
[34]常宝成.胰岛素增敏剂——罗格列酮在糖尿病中的应用[J].国外医学内分泌学,2001,21:35.
[35]王宪,高孝斗,许华强,等.拜糖平治疗2型糖尿病的临床观察[J].中原医刊,2001,29(2):22.
[36]李妍,苏乐群.胰岛素抵抗的药物治疗[J].山东医药工业,2001,1(20):26-28.
[37]Yavuz D,Koc M,Topmk A,et al.Efects of ACE inhibition and AT1-recept oran tagonism on endothelial function and insulin sensitivity in essential hype sensiv e atients[J].J Renin Angiotensin Aldosterone Syst,2003,4(3):197-203.
[38]Howlett KF,W att MJ,Hargreaves M,el al.Regulation of glucose kinetics during itense exercise in humans:efects of alpha-and betaadrenergicblockade[J].Met abolism,2003,52(12):1615-1620.
[39]沈稚舟,吴松华,邵福源,等.糖尿病慢性并发症.上海:上海医科大学出版社,1999:1024-1027.
[40]叶山东,朱禧星.临床糖尿病学.安徽:安徽科学技术出版社,2005:177-181.
[41]李以肚.成年病治疗药的开发概况(续)国外医药一台成药、生化药、制剂分册,1995.16(1):20.
[42]赵晶,戴德哉.糖尿病并发症的药物治疗.药学进展,2003,27(2):88-91.
[43]Reynolds lames EF Mardnda[e the ext T～pharmacopoeia 31st ed London:Ph～aaceutical Press.1996:342.
[44]彭亚贞,史玉曼.糖尿病并发症治疗的成功和失败经验[J].医药工业科研开发信息,1998,(1):36.
[45]Pieper G M,Langenstroer P,SiebeneichW.Diabetic-inducedendoth elial dysfun ction in rat aorta:role of hydroxyl radicals[J].Card/ovasc Res,1997,34(1):145-156.
[46]陈长青,熊曼琪,李赛美,等.消渴病(糖尿病)的病机研究进展[J].中国中医基础医学杂志,2002,8(10):72-73.
[47]熊曼琪.脾虚是消渴病的重要病机[J].广州中医学院学报,1991,(7):13-14.
[48]潘朝曦.糖尿病病因、病机、治法新探[J].江苏中医,2000,21(1):1-3.
[49]陈汉桥.肝气郁结与消渴病关系的理论研究[J].江苏中医,1997,18(9):49-50.
[50]邹如政.糖尿病从肝论治[J].中国医药学报,1998,13(1):17-23.
[51]张鸿恩.糖尿病中医病机探讨[J].吉林中医药,1989,(1):11-12.
[52]周叔平.试论糖尿病气虚为本[J].新中医,1999,31(2):5-6.(1):25-27.
[53]曹忠贞.论消渴与痰[J].中医药研究,1997,13(2):8-9.
[54]金学仁.略论糖尿病与湿[J].江南中医,1993,(1):6-7.
[55]徐正正.不同病程糖尿病患者的征候特征[J].中医杂志,200,41(1):44-45
[56]王如沾.论毒与糖尿病[J].山东中医杂志,1999,18(8):339-341.8-9.
[57]魏军平.62例糖尿病患者血液流变学观察[J].辽宁中医杂志,1993,11(8):29
[58]梁晓春,郭赛珊,王香定.糖尿病患者血浆TXB2、6-keto-PGF-la水平、全血粘度与血瘀证及微血管病的关系[J].中西医结合杂志,1992(5):297-299.
[59]顾士芬.糖尿病患者甲皱微循环观察[J].江苏医药,19911(5):15-17.
[60]王柏生.糖尿病患者血液流变学和甲皱微循环的改变[J].临床医学,1987(2):95-99.
[61]俞亚琴,王彬.从血瘀角度探讨Ⅱ型糖尿病胰岛素抵抗[J].浙江中医杂志,2002:175-176.
[62]何晓兰.活血化瘀法治疗老年糖尿病54例[J].辽宁中医杂志,1996;(4):16.
[63]王开锋.水蛭三黄汤治疗糖尿病20例临床分析[J].湖南中医杂志,1993,6(9):2-4.
[64]祁松强.从瘀论治糖尿病[J].实用中西医杂志,1996,8(9):493-495.
[65]李惠林,熊曼琪,邓尚平,等.加味桃核承气汤对实验性糖尿病大鼠胰岛素受体的影响[J].中国中西医结合杂志,1995,15:338-340.
[66]鲁瑾,邹大进,张家庆,等.黄芪预防肿瘤坏死因子—2所致胰岛素抵抗[J].中国中西结合杂志,1999,19(7):420.
[67]王凌,李秋贵,浦信行,等.参地降糖颗粒对高果糖大鼠胰岛素抵抗的影响[J].中医杂志,2001,42(11):686.
[68]钱东生.山茱萸乙醇提取液对NIDDN大鼠骨骼肌GLUT4表达影响的实验研究[J].中国中药杂志,2001,26(12):85.
[69]李宗友.胡芦巴抗糖尿病和降胆固醇作用[J].国外医学中医中药分册,1999,21(4):9-13.
[70]李真,马高峰.生地黄连液对四氧嘧啶小鼠影响的实验研究[J].辽宁中医杂志,2000,27(12):573-574.
[70]宋福印.消渴停对胰岛8细胞凋亡及相关基因Bcl-2,Fas蛋白表达的影响[J].中国中医药信息杂志,2001,8(6):24.
[72]尚文斌,金妙方,方泰惠,等.糖渴清降血糖机制的实验研究[J].中药药理与临床,1996,(4):31-33.
[73]张冰,高光艳,江佩芬.菊苣胶囊对小鼠血糖水平的影响[J].北京中医药大学学报,1999,22(1):28-30.
[74]沈忠明,李英,姜宏.降糖中药对a-葡萄糖苷酶抑制作用的研究[J].中国生化药物杂志,2000,21(2):69-70.
[75]梁晓春,郭赛珊,王香定,等.金芪降糖片治疗气阴两虚火旺型糖尿病临床及实验研究[J].中国中西医结合杂志,1993.13(10):587.
[76]季绍良,陈易新.中药新药的分类与选题立项[J].中国中医药信息杂志,2000,7(1):14.
[77]周华容,钟国跃.浅析糖尿病中成药的开发[J].世界科学技术—中医药现代化(思路与方法),2003,5(5):18-23.
[78]魏子孝.立足医疗实际对糖尿病中药新药开发的思考[J].中国现代临床医学,2004,3(11):39-40.
[79]李天庆,崔听,张志军,等.汉方药治疗糖尿病及其并发症的研究[J].国外医药·中医中药分册,1997,19(6):3-7.
[80]陈广耀.抗糖尿病中药开发前景展望[J].中国新药杂志,2000,9(7):448-451.
[81]王启慧.糖尿病单味中药作用机制研究概述[J].安徽中医学院学报,1999,18(4):58-59.
[82]洪浩.中药降血糖作用机制实验研究进展[J].安徽中医学院学报,2001,20(2):59-61.
[83]曹勇.中医药降糖机理及免疫调节[J].中医药学报,1994,22(1):9-12.
[84]郭舜民,郭尧惠.天然药降血糖成分的研究进展[J].海峡药学,2000,12(10):1-5.
[85]魏子孝.试谈“辨病与辨证相结合”的中医治疗思路模式[J].中华临床医学杂志,2006,37(3):87-89.
[86]陈长青.消渴病(糖尿病)病机探讨—附32例病例报告[J].中医药研究.1997,13(5):4-6.
[87]柴佩芳,胡德培,陈灏珠,等.糖尿病合并心脑血管疾病的多种因素[J].上海医科大学学报,1998,25(3):240.
[88]李正喜.复方丹参片治疗老年性心脑血管病133例疗效观察[J].贵州医药,1989,13(2):121-122.
[89]张翼鹿.复方丹参片治疗颅脑外伤后神衰综合症122例[J].云南中医杂志,1984,5(5):24-26.
[90]魏德新.克朗宁并复方丹参片治疗脂肪肝49例[J].中国中西医结合杂志2000:20(10):78-789.
[91]周幼龙.非诺贝特片及复丹参片治疗脂肪肝156～J疗效观察[J].山西临床医药,2002,11(6):438-439.
[92]孔武明,龚均,董蕾.复方丹参片联合维生素E对慢性乙型肝炎肝纤维化的影响研究[J].中国实用内科杂志,2005,25(9):799-801.
[93]孙权.促肝细胞生长素联合复方丹参片治疗肝硬变腹水32例[J].中西医结合杂志,1998增刊(下):165.
[94]成娟.肝苏颗粒联合复方丹参片治疗肝纤维化28例[J].江西中医学院学报,2000:12(3):7.
[95]谭孝.硝苯地平和复方丹参片治疗老年高血压临床分析[J].中国现代医学杂志, 1998:8(6):69-70.
[96]洪梅.复方丹参片治疗恢复期妊高征疗效观察[J].河南实用神经杂志,2002:5(2):66.
[97]曹银娥.复方丹参片治疗老年皮肤瘙痒症[J].山东医药,1997:37(8):62-63.
[98]张青文,刘奇莉.复方丹参片治疗胃肠痉挛性腹痛[J].中国乡村医药.
[99]李立东.复方丹参片治疗Colles骨折疗效观察[J].交通医学,1999:13(1):120.
[100]倪秀英,郑荣.复方丹参片治疗Ⅰ型慢性精神分裂症效果观察[J].海峡药学,2001:13(4):31.
[101]梅全喜.复方丹参片的新用途.家庭中医药,2002,12(9):52.
[102]宋怀方,林令华.复方丹参片对糖尿病人超氧化物歧化酶活力及血液流变学的影响[J][J].药学进展,2000,24(3):170-172.
[103]王筠默.复方丹参片的药理作用研究[J].中成药研究,1984,(11):22-24.
[104]于培兰.丹参对小鼠耐急性重复性缺氧能力形成的[J].首都医科大学学报,2001:22(1):65-66.
[105]潘文军.复方丹参片对家兔实验性心肌梗塞和心肌酶谱的影响[J].沈阳药科大学学报 2005,22(1):53-55.
[106]高秀梅.复方丹参方抗大鼠心肌缺血作用[J].天津中医药,2003:(1):23-42.
[107]张昱.复方丹参片对大鼠心肌缺血再灌注损伤的保护[J].河南中医药学刊,1997:12(6):15-17.
[108]范照冬.复方丹参片对大鼠实验性脑缺血的保护作用研究[J].山西职工医学院学报,2000,10(2):3-4.
[109]朱永林.复方丹参片对慢性脑缺血大鼠脑内HIF-1α表达的影响[J].实用神经疾病杂志,2005,8(5):18-19.
[110]屈彩琴.复方丹参片对大鼠实验性血栓形成的[J].河北中医,1999,21(4):252.
[111]覃仁安.复方丹参片对阿尔茨海默病大鼠脑内氨基酸类神经递质含量的影响[J].中草药,2004,35(8):905-908.
[112]覃仁安.复方丹参片对阿尔茨海默病大鼠学习记忆障碍和脑组织β-AP含量的影响[J].中华中医药杂志,2005,20(6):377-378.
[113]杨桂珍,黄科军.复方丹参片对糖尿病大鼠坐骨神经和红细胞山梨醇浓度的影响[J].中国老年学杂志,2007,27(1):33-34.
[114]杨桂珍,吴莉.复方丹参片对实验性糖尿病大鼠LP0含量及SOD水平的影响[J].陕西中医,2007,28(3):372-374.
[115]郑虎占,董泽宏,祭靖.中药现代研究与应用.第2卷.北京:学苑出版社.1997.10.
[116]林佳,徐丽珍,李琰,等.不同产地丹参中丹参酮Ⅱ_A的含量比较[J].中国中药学杂志,2002,27(2):153-154.
[117]孙学刚,贾钰华,陈育鹩.定心方及丹参酮对血小板膜粘附分子表达的影响[J].山东中医药大学学报,2001,25(1):61-63.
[118]姜开余,阮长耿,陈振纶,等.丹参酮ⅡA磺酸钠对内皮细胞和血小板体外表达粘附分子的作用[J].中国药理学报,1998,19(1):47-50.
[119]吴平生,梁欣伟,郭志刚,等.丹参酮ⅡA抑制血管合成醛固酮及醛固酮合成酶基因CYP11B2信使核糖核酸表达[J].中国循环杂志,1998,13(3):175-177.
[120]费丽萍,李进禧,郑道声,等.丹参酮ⅡA磺酸钠对红细胞内游离钙浓度的影响[J].微循环学杂志,1997,7(4):17-19.
[121]斐文芬,孔德虎,鄢顺勤,等.丹参酮Ⅱ—A豚鼠交感椎前神经节细胞膜电位的影响[J].安徽中医学院学报,1996,15(4):55-56.
[122]赵燕,江文,侯京武,等.钙过负荷和丹参酮对线粒体脂质过氧化影响[J].生物化学与生物物理学报,1995,27(6):610.
[123]王军,邱玉兰.丹参酮对实验性脑梗塞大鼠血液发光学的影响[J].中药药理与临床,1999,15(4):29-30.
[124]徐罗玲,吴琦,王佰瑶,等.丹参酮对人中性粒细胞氧自由基释放的抑制效应[J].中国病理生理杂志,1994,10(6):635-638.
[125]钟先阳,罗仁,魏华.丹参酮ⅡA对大鼠出血性休克再灌注肾损伤的保护作用[J].辽宁中医杂志,2002,29(8):505-506.
[126]钟先阳,罗仁,魏连波.丹参酮ⅡA对大鼠出血性休克一再灌注肾损伤的防治作用[J].中国中西医结合肾病杂志,2002,3(1):13-15.
[127]何丽娜,扬军,姜怡,等.丹参酮对培养PCL2细胞损伤的保护作用[J].中国中药杂志,2001,26(6):413-416.
[128]何丽娜,何素冰,扬军.丹参酮对氯化钾及N-甲基-D-门冬氨酸诱导PCL2细胞钙超载损伤的保护作用[J].中国现代应用药学杂志,2001,18(3):179-181.
[129]何素冰,何丽娜,扬军.丹参酮对大鼠皮层神经细胞钙超载损伤的保护作用[J].中成药,2002,24(5):371-373.
[130]吴世蓉.不同产地丹参其主要化学成分的分离与测定[J].基层中药杂志,2002,16(3):24.
[131]黄诒林,张均田.丹参中三种水溶性成分的体外抗氧化作用[J].药学学报,1992,27(2):96-100.
[132]李静,何丽一,宋万志.丹参中水溶性酚酸类成分的薄层扫描测定法[J].药学学报,1993,28(7):543-547.
[133]桂冠华.张均田.丹酚酸A对钠钾ATP酶活性及基因表达的影响[J].中国病理 生理杂志,1998,14(7):862.
[134]王洁.张均田.总丹酚酸抗脑缺血与抗血栓的关系[J].中国药理学通报,1999,15:204-206.
[135]王浩,张均田.总丹酚酸的抗脑缺血和抑制谷氨酸释放作用[J].中国药理学与毒理学杂志,1999,15:164:166.
[136]YokozawaT.LeTw.Efectofmagnesiumlithospermate B on the renal and urinary kallikrein activities in rats with adenine·induced renal failure[J].Nippon J Jnzo Gak kai Shi 1993.35:337-342.
[137]Yokozawa T,Yasui T,Oura H.Molecular biological analysis of the effects o f ginsenoside -Rb2 on albumin mRNA in streptozotoci-ninduced diabetic rats[J].JPh arm Pharmacol,1996,48:763-767.
[138]Kenarova B,Neychev H,Hadjiivanova C,et al.Immunomodulating activity of ginsenoside Rg1 from Panaxginseng[J].Jpn J Pharmacol,1990,54:447-454.
[139]Zhang HG,Li XH,Yang ZC.Effects of Panax notoginseng on myocardial Gs a mRNA expression and ATPase activity after severe cald in rats[J].Burns,2003,29:541-546.
[140]林曙光.三七皂苷对高脂血清所致的培养主动脉平滑肌细胞增殖的作用[J].中国药理学报,1993,14(4):314-316.
[141]张林波,杨贵贞.三七皂甙Rg1纹状体内注射对帕金森病模型大鼠免疫炎症损伤的拮抗效应[J].中国免疫学杂志,2004,20(2):121-123.
[142]武杰雄,孙家均.PNS、维拉帕米、去甲肾上腺素对大鼠和家兔脑循环的作用比较[J].中国药理学报,1992,13(6):520-523.
[143]Hua JA,Hu WY,Sun ZH.Effect of Panax notoginseng Saponin on Ca2+,CaM in craniocerebral injury[J].Chinese Journal of Integrated Traditional and West em Medicine,1999,19:227-229.
[144]邹玉安,魏阿平.三七皂苷对大鼠缺血脑组织呈氧化氮表达的影响[J].脑与神经疾病杂志,2000,8(4):196-200.
[145]Zhang GQ,Ye RG,Kong QY,et al.Panax notoginseng saponins induced of human renal interstitial fibroblasts and its mechanisms[J].Chinese Journal of Nephr ology,1998,14:93-95.
[146]刘启德,梁美蓉,陈芝喜,等.冰片对庆大霉素透血脑屏障的影响[J].广州中医学院学报,1994,11(1):37-40.
[147]黎新荣,徐伟,冯毅凡,等.冰片及薄荷醇对尼群地平在家兔体内吸收的影响[J].中国医院药学杂志,2001,21(5):264-266.
[148]王原,吴伟康,黄志宏,等.冰片在正常人皮肤增加曲安缩松的透皮生物利用度[J].中药药理与临床,1992,8(特辑):178.
[149]王晖,许卫铭,王宗锐,等.薄荷醇与冰片的促透作用[J].中草药,1997.28(2):93-95.
[150]朱健平,王宗锐,吴宋夏.龙脑促进药物经皮渗透作用的研究[J].中国药学杂志,1999,34(2):104-106.
[151]江文德,徐端正,胡国钧,等.冠心苏合丸的药理研究及其简化制剂—苏冰滴丸的理论基础[J].药学学报,1979,14(11):655-60.
[152]邓文龙.开窍方药的临床及实验研究进展[J].中成药研究,1985,(3)133-38.
[153]江光池,冯旭军,黄岚,等.龙脑和异龙脑对小鼠和家兔的药理作用[J].华西药学杂志,1989,4(1):23-25.
[154]江光池,杨胜华,冯旭军.龙脑和异龙脑的抗炎作用[J].华西药学杂志,1990,5(3):190-191.
[155]叶任高,主编.内科学[M].第5版.北京:人民卫生出版社,2000,798-810.
[156]卫生部.1996～2000国家糖尿病防治规划纲要[J].中国公共卫生管理,1997,13:149.
[157]李光伟,潘孝仁.测人群瞳岛索敏感性的一项新指标[J].中华内科杂志,1993,32(10):655.
[158]黄松.糖尿病动物模型研究现状及进展[J].广西医学,2002,24(1):46-48.
[159]杨竹林,伍汉文,周智广,等.完全弗氏佐剂预防NOD鼠胰岛炎和糖尿病的机理研究[J].中华内分泌代谢杂志,1999,15(5):2713.
[160]郑里祥.STZ和Alloxan联合使用复制实验性糖尿病大鼠模型[J].中国病理生理杂志,1999,15(8):758.
[161]都健,赵玉岩,谢辉,赵谨.喂养型胰岛素抵抗动物模型的建立与评价[J].中国医科大学学报,2002,31(5):343.
[162]司晓晨,尚文斌,卞慧敏,等.链脲佐菌素加高脂膳食诱导2型糖尿病大鼠模型[J].安徽中医临床杂志,2003,15(5):383.
[163]蔡文就,熊曼琪,朱章志,等.实验性NIDDM大鼠模型及其胰岛素抵抗的初步研究[J].广州中医药大学学报,1997,14(2):87.
[164]霍建新,唐静晓.郭永强.药物治疗糖尿病性视网膜病变的现状[J].包头医学院学院,2003,4(1):236-237.
[165]张军,王凤云,肖凤霞.丹参药材提取液中丹参酚酸大孔树脂吸附工艺研究[J].中药新药与临床药理,2005,12(3):263-265.
[166]刘睿,高巨,王春红,等.G-821树脂提取三七叶皂苷的工艺研究[J].中草药,2007,38(7):1026-1028.